Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Therapeutic vaccination with 4-1BB co-stimulation eradicates mouse acute myeloid leukemia.

Kerage D, Soon MSF, Doff BL, Kobayashi T, Nissen MD, Lam PY, Leggatt GR, Mattarollo SR.

Oncoimmunology. 2018 Jul 26;7(10):e1486952. doi: 10.1080/2162402X.2018.1486952. eCollection 2018.

2.

B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity.

McKee SJ, Tuong ZK, Kobayashi T, Doff BL, Soon MS, Nissen M, Lam PY, Keane C, Vari F, Moi D, Mazzieri R, Leggatt G, Gandhi MK, Mattarollo SR.

Oncoimmunology. 2017 Dec 18;7(2):e1393599. doi: 10.1080/2162402X.2017.1393599. eCollection 2018.

3.

Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.

McKee SJ, Doff BL, Soon MS, Mattarollo SR.

Cancer Immunol Res. 2017 Mar;5(3):191-197. doi: 10.1158/2326-6066.CIR-16-0249. Epub 2017 Jan 23.

4.

NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.

Kobayashi T, Doff BL, Rearden RC, Leggatt GR, Mattarollo SR.

Oncoimmunology. 2015 Jan 7;4(3):e990793. eCollection 2015 Mar.

Supplemental Content

Support Center